[ad_1] AstraZeneca Plc (LON:AZN) announced today positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the …
Read More »AstraZeneca diabetes drug cuts complications
[ad_1] A drug developed by AstraZeneca has markedly reduced the chances of diabetic patients being hospitalized with heart failure, a condition badociated with type 2 diabetes. The findings, from a large clinical …
Read More »